초록 ▼

An immunochemical process and compositions for determining rapidly and accurately the amount of creatine kinase-MB isoenzyme (CK-MB) in biological fluids. The process employs a triple antibody technique which leads to the formation of an immuno-complex having a measurable label. This process and the

An immunochemical process and compositions for determining rapidly and accurately the amount of creatine kinase-MB isoenzyme (CK-MB) in biological fluids. The process employs a triple antibody technique which leads to the formation of an immuno-complex having a measurable label. This process and the resulting complex are useful in determining whether a patient has suffered a myocardial infarct.

대표청구항 ▼

A process for determining the amount of creatine kinase-MB isoenzyme in a biological fluid sample containing creatine kinase having subunit B or M or both, the process comprising: (a) incubating the sample with (i) a first antibody raised in a first animal species, the first antibody capable of immu

A process for determining the amount of creatine kinase-MB isoenzyme in a biological fluid sample containing creatine kinase having subunit B or M or both, the process comprising: (a) incubating the sample with (i) a first antibody raised in a first animal species, the first antibody capable of immuno-reactively binding selectively one of the B or M subunits of the creatine kinase in the sample; (ii) a second antibody raised in a second animal species, the second antibody capable of immunoreactively binding selectively as an immunoprecipitin with the first antibody; and (iii) a third antibody raised in an animal species other than the first animal species and labeled with a measurable label, the third antibody capable of immunoreactively binding selectively with the other of said M or B subunits to provide as a precipitate a mixture of immuno-complexes containing labeled third antibody-creatine kinase-MB isoenzyme-first antibody-second antibody and creatine kinase isoenzyme-first antibody-second antibody; (b) isolating the precipitate containing the immunocomplexes; (c) measuring the amount of label in the precipitate; and (d) comparing the amount of measured label to a standard curve thereby determining the amount of creatine kinase-MB isoenzyme in the biological fluid sample.